SMT202000529T1 - Composti di 6-eterociclil-4-morfolina-4-ilpiridin-2-one utili per il trattamento di cancro e diabete - Google Patents

Composti di 6-eterociclil-4-morfolina-4-ilpiridin-2-one utili per il trattamento di cancro e diabete

Info

Publication number: SMT202000529T1
Authority: SM; San Marino
Prior art keywords: ylpyridin; morpholin; heterocyclyl; diabetes; cancer
Prior art date: 2016-02-19

Application number

SM20200529T

Other languages

English (en)

Inventor

Jessica Martinsson

Martin Andersson

Johan Lindström

Rickard Forsblom

Fredrik Rahm

Tobias Ginman

Jenny Viklund

Original Assignee

Sprint Bioscience Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-19

Filing date

2017-02-17

Publication date

2020-11-10

2017-02-17 Application filed by Sprint Bioscience Ab filed Critical Sprint Bioscience Ab

2020-11-10 Publication of SMT202000529T1 publication Critical patent/SMT202000529T1/it

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Oncology (AREA)
Inorganic Chemistry (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Heart & Thoracic Surgery (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SM20200529T 2016-02-19 2017-02-17 Composti di 6-eterociclil-4-morfolina-4-ilpiridin-2-one utili per il trattamento di cancro e diabete SMT202000529T1 (it)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP16156533		2016-02-19
EP17704791.7A EP3416957B1 (en)	2016-02-19	2017-02-17	6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes
PCT/EP2017/053614 WO2017140843A1 (en)	2016-02-19	2017-02-17	6-heterocyclyl-4-morpholin-4-ylpyridine-2-one compounds useful for the treatment of cancer and diabetes

Publications (1)

Publication Number	Publication Date
SMT202000529T1 true SMT202000529T1 (it)	2020-11-10

Family

ID=55404646

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SM20200529T SMT202000529T1 (it)	2016-02-19	2017-02-17	Composti di 6-eterociclil-4-morfolina-4-ilpiridin-2-one utili per il trattamento di cancro e diabete

Country Status (19)

Country	Link
US (2)	US11179399B2 (it)
EP (1)	EP3416957B1 (it)
JP (1)	JP6858984B2 (it)
CN (1)	CN108884067B (it)
AU (1)	AU2017219847B2 (it)
CY (1)	CY1123349T1 (it)
DK (1)	DK3416957T3 (it)
ES (1)	ES2821400T3 (it)
HR (1)	HRP20201430T1 (it)
HU (1)	HUE051059T2 (it)
LT (1)	LT3416957T (it)
PL (1)	PL3416957T3 (it)
PT (1)	PT3416957T (it)
RS (1)	RS60900B1 (it)
RU (1)	RU2762968C2 (it)
SI (1)	SI3416957T1 (it)
SM (1)	SMT202000529T1 (it)
TW (1)	TWI723131B (it)
WO (1)	WO2017140843A1 (it)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT3416957T (pt) *	2016-02-19	2020-09-25	Sprint Bioscience Ab	Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes
EP4056556A1 (en)	2017-08-23	2022-09-14	Sprint Bioscience AB	Pyridylpyridone compounds
HRP20211999T1 (hr)	2017-08-23	2022-04-01	Sprint Bioscience Ab	Spojevi azaindolilpiridona i diazaindolilpiridona
PL3672948T3 (pl)	2017-08-23	2022-12-05	Sprint Bioscience Ab	Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
CN116462674A (zh) *	2017-08-23	2023-07-21	思普瑞特生物科学公司	吗啉基吡啶酮化合物
WO2019199864A1 (en)	2018-04-10	2019-10-17	Neuropore Therapies, Inc.	Tri-substituted aryl and heteroaryl derivatives as modulators of pi3-kinase and autophagy pathways
CA3095512A1 (en) *	2018-04-10	2019-10-17	Neuropore Therapies, Inc.	Morpholine derivates as inhibitors of vps34
WO2020008046A1 (en)	2018-07-06	2020-01-09	Sprint Bioscience Ab	Biomarker
ES3023544T3 (en) *	2019-12-04	2025-06-02	Chdi Foundation Inc	Atm kinase inhibitors and compositions and methods of use thereof
EP4251165A1 (en) *	2020-11-25	2023-10-04	Deciphera Pharmaceuticals, LLC	Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
EP4251166A1 (en) *	2020-11-25	2023-10-04	Deciphera Pharmaceuticals, LLC	Morpholino derivatives as vsp34 inhibitors for use in the treatment of a viral infection
US11801238B2 (en)	2020-11-25	2023-10-31	Deciphera Pharmaceuticals, Llc	Anti-viral activity of VPS34 inhibitors
AU2022326573A1 (en)	2021-08-13	2024-02-15	Deciphera Pharmaceuticals, Llc	Combination therapy of vps34 inhibitors and sting agonist for use in the treatment of cancer

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7423148B2 (en)	2002-11-21	2008-09-09	Chiron Corporation	Small molecule PI 3-kinase inhibitors and methods of their use
GB2465405A (en)	2008-11-10	2010-05-19	Univ Basel	Triazine, pyrimidine and pyridine analogues and their use in therapy
MY155661A (en) *	2009-07-02	2015-11-13	Sanofi Sa	Novel 1,2,3,4-tetrahydropyrimido{1,2-a}pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof
EP2655340B1 (en)	2010-12-21	2015-01-21	Novartis AG	Bi-heteroaryl compounds as vps34 inhibitors
WO2012085244A1 (fr)	2010-12-23	2012-06-28	Sanofi	Derives de pyrimidinone, leur preparation et leur utilisation pharmaceutique
GB201120317D0 (en)	2011-11-24	2012-01-04	Queen Mary & Westfield College	Screening method
FR2992314B1 (fr) *	2012-06-22	2015-10-16	Sanofi Sa	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
US9242969B2 (en)	2013-03-14	2016-01-26	Novartis Ag	Biaryl amide compounds as kinase inhibitors
EP3042900B1 (en) *	2013-08-29	2020-09-23	Fujifilm Corporation	Novel morpholine derivative or salt thereof
CR20160363A (es)	2014-01-14	2016-10-12	Millennium Pharm Inc	Heteroarilos y usos de estos
EP3094326A4 (en)	2014-01-14	2017-07-26	Millennium Pharmaceuticals, Inc.	Heteroaryls and uses thereof
MA39823A (fr)	2014-04-03	2018-01-09	Janssen Pharmaceutica Nv	Dérivés de pyridine macrocyclique
MA39822A (fr)	2014-04-03	2018-02-06	Janssen Pharmaceutica Nv	Dérivés de pyrimidine bicycle
MX2017003624A (es)	2014-09-17	2017-07-13	Verseon Corp	Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
AU2017219846B2 (en) *	2016-02-19	2021-05-13	Sprint Bioscience Ab	6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes
PT3416957T (pt) *	2016-02-19	2020-09-25	Sprint Bioscience Ab	Compostos 6-heterociclil-4-morfolin-4-ilpiridin-2-ona úteis para o tratamento do cancro e da diabetes

2017
- 2017-02-17 PT PT177047917T patent/PT3416957T/pt unknown
- 2017-02-17 TW TW106105178A patent/TWI723131B/zh not_active IP Right Cessation
- 2017-02-17 AU AU2017219847A patent/AU2017219847B2/en active Active
- 2017-02-17 WO PCT/EP2017/053614 patent/WO2017140843A1/en not_active Ceased
- 2017-02-17 CN CN201780015103.7A patent/CN108884067B/zh active Active
- 2017-02-17 HU HUE17704791A patent/HUE051059T2/hu unknown
- 2017-02-17 RU RU2018131766A patent/RU2762968C2/ru active
- 2017-02-17 SM SM20200529T patent/SMT202000529T1/it unknown
- 2017-02-17 HR HRP20201430TT patent/HRP20201430T1/hr unknown
- 2017-02-17 JP JP2018562702A patent/JP6858984B2/ja active Active
- 2017-02-17 SI SI201730405T patent/SI3416957T1/sl unknown
- 2017-02-17 EP EP17704791.7A patent/EP3416957B1/en active Active
- 2017-02-17 PL PL17704791T patent/PL3416957T3/pl unknown
- 2017-02-17 RS RS20201061A patent/RS60900B1/sr unknown
- 2017-02-17 LT LTEP17704791.7T patent/LT3416957T/lt unknown
- 2017-02-17 DK DK17704791.7T patent/DK3416957T3/da active
- 2017-02-17 ES ES17704791T patent/ES2821400T3/es active Active
- 2017-02-17 US US15/999,432 patent/US11179399B2/en active Active
2020
- 2020-09-15 CY CY20201100870T patent/CY1123349T1/el unknown
2021
- 2021-10-14 US US17/501,407 patent/US11963963B2/en active Active

Also Published As

Publication number	Publication date
HUE051059T2 (hu)	2021-03-01
DK3416957T3 (da)	2020-09-21
AU2017219847B2 (en)	2021-02-04
SI3416957T1 (sl)	2020-11-30
CN108884067B (zh)	2021-01-08
TW201731843A (zh)	2017-09-16
RU2018131766A3 (it)	2020-03-24
JP2019505595A (ja)	2019-02-28
RU2762968C2 (ru)	2021-12-24
ES2821400T3 (es)	2021-04-26
RU2018131766A (ru)	2020-03-20
EP3416957B1 (en)	2020-07-01
CA3015005A1 (en)	2017-08-24
US20210161906A1 (en)	2021-06-03
AU2017219847A1 (en)	2018-10-04
PL3416957T3 (pl)	2021-02-08
TWI723131B (zh)	2021-04-01
PT3416957T (pt)	2020-09-25
CY1123349T1 (el)	2021-12-31
JP6858984B2 (ja)	2021-04-14
US11963963B2 (en)	2024-04-23
WO2017140843A1 (en)	2017-08-24
EP3416957A1 (en)	2018-12-26
US11179399B2 (en)	2021-11-23
CN108884067A (zh)	2018-11-23
LT3416957T (lt)	2020-11-25
US20220175788A1 (en)	2022-06-09
HRP20201430T1 (hr)	2020-11-27
RS60900B1 (sr)	2020-11-30

Publication	Publication Date	Title
IL264674B1 (en)	2023-05-01	Antibodies to siglec7 for cancer treatment
ZA201806819B (en)	2022-03-30	Pharmaceutical combinations for the treatment of cancer
PL3416957T3 (pl)	2021-02-08	Związki 6-heterocyklilo-4-morfolino-4-ylopirydyn-2-onu przydatne w leczeniu raka i cukrzycy
ZA201607415B (en)	2019-06-26	Antibody-drug-conjugate and its use for the treatment of cancer
EP3402516A4 (en)	2020-01-08	USE OF ANTIBODIES DIRECTED AGAINST SIGLEC-7 OR SIGLEC-9 IN THE TREATMENT OF CANCER
IL256224B (en)	2022-06-01	Combined therapy for cancer treatment
PT3416945T (pt)	2020-09-11	Compostos de 6-aril-4-(morfolin-4-il)-1h-piridina-2-ona úteis para o tratamento do cancro e da diabetes
IL261959B1 (en)	2023-04-01	Cancer treatment with tg02
IL258521A (en)	2018-05-31	Combination of treatments for cancer treatment
IL259996A (en)	2018-07-31	Combinations for cancer treatment
EP3157336A4 (en)	2018-01-24	Oxabicycloheptanes and oxabicycloheptenes for the treatment of ovarian cancer
IL263793A (en)	2019-01-31	Compounds and preparations for the treatment of cancer
GB201612165D0 (en)	2016-08-24	Combinations for the treatment of type 2 diabetes
IL280587B (en)	2021-10-31	Fluorocitidine derivatives and their preparations for use in cancer treatment
ZA201901578B (en)	2022-04-28	Combinations including abx196 for the treatment of cancer
PL3630754T3 (pl)	2022-10-24	Związki izoindolinoacetylenowe do leczenia nowotworu
IL252493B (en)	2020-04-30	Compounds for use in the prevention or treatment of cancer
EP3242681B8 (en)	2020-11-25	Novel compounds for the treatment of cancer
ZA201704589B (en)	2019-02-27	Compounds for the treatment of cancer
HK40001850B (en)	2021-02-11	6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes
HK40001850A (en)	2020-03-13	6-heterocyclyl-4-morpholin-4-ylpyridin-2-one compounds useful for the treatment of cancer and diabetes
GB201713936D0 (en)	2017-10-18	Pharmaceutical combinations for the treatment of cancer
GB201603882D0 (en)	2016-04-20	Compounds for the treatment of type 2 diabetes